General Federal Contracts — September 03, 2026

Walgreens received a $290.9 million firm-fixed-price contract from the CDC, fully obligated and outlayed, providing high revenue certainty through May 2025. This represents approximately $96.9 million in annual revenue for the company.

The contract is firm-fixed-price, which offers margin upside if Walgreens manages costs efficiently but carries risk of cost overruns if execution challenges arise. This is a medium-risk pricing structure for a $290.9M obligation.

Walgreens faces medium execution risk on the $290.9M firm-fixed-price CDC contract. Cost overruns could compress margins on this fully obligated award.

This single $290.9M contract represents a significant concentration of revenue from one civilian agency (CDC) for Walgreens' government services segment. Loss of this contract would materially impact that revenue stream.

Walgreens' competitive win of this $290.9M CDC contract via full and open competition demonstrates its ability to secure large civilian health contracts. This could lead to follow-on awards or expansion into other CDC programs.

The CDC's full obligation of a $290.9M contract to Walgreens demonstrates continued funding commitment to specialized medical support services under the ICATT program, despite broader budget uncertainty.

{"entity" => "Walgreens Boots Alliance", "reason" => "The $290.9M CDC contract provides significant revenue visibility through May 2025, but the fixed-price structure and potential re-compete create uncertainty.", "trigger" => "Q2 2025 earnings call for contract renewal discussion; CDC FY2025 budget release for ICATT program funding levels"}

{"entity" => "CVS Health", "reason" => "As a direct competitor to Walgreens in the retail pharmacy and health services space, CVS may bid on similar CDC contracts or the ICATT re-compete.", "trigger" => "Announcement of similar CDC contract awards to CVS or other competitors"}